GlassScriptPhysician profile
Neha P Sheth
NPI 1447220579
$3,247.56
in general payments reported to CMS, 2019-2025
23 companies · $957 in 2025
The $957 reported for 2025 was more than what 90% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $533 · 2020: $213 · 2021: $181 · 2022: $489 · 2023: $257 · 2024: $617 · 2025: $957.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,832.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,831.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $442.22 | 2019-2025 | Myday Contact Lens, Paragon Crt, Misight Contact Lens |
| Alcon Vision LLC | $434.41 | 2021-2025 | Tryptyr, Total30, Precision 1 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $339.07 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $274.19 | 2022-2025 | Infuse, Xiidra, Miebo |
| Topcon Healthcare, INC. | $215.30 | 2024 | |
| Tarsus Pharmaceuticals, INC. | $152.60 | 2024-2025 | Xdemvy |
| Ocular Therapeutix, INC. | $150.00 | 2025 | Dextenza |
| Rxsight INC | $146.76 | 2024 | Rxsight Injector Cartridge, Rxsight Contact Lens, Light Adjustable Lens (Lal) |
| Visioneering Technologies, INC. | $146.24 | 2019-2020 | |
| Lkc Technologies, INC. | $133.45 | 2024 | |
| Myovant Sciences INC. | $127.20 | 2022 | |
| Avion Pharmaceuticals | $123.03 | 2021-2022 | |
| Amgen INC. | $117.68 | 2025 | Tepezza |
| Asd Specialty Healthcare, LLC | $104.50 | 2019 | |
| Glaukos Corporation | $100.37 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $91.00 | 2021 | |
| Sumitomo Pharma America, INC. | $50.88 | 2023 | Myfembree |
| Oyster Point Pharma, INC. | $26.87 | 2022 | |
| Allergan, INC. | $15.66 | 2022 | |
| Sight Sciences, INC. | $14.74 | 2024 | Omni Surgical System |
| Johnson & Johnson Vision Care, INC. | $14.65 | 2022 | |
| Biotissue Holdings INC. | $13.54 | 2023 | |
| Coopersurgical, INC. | $13.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neha Sheth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.